The fattish obesity opportunity!
22/11/22 -"While diabetes has been Novo’s traditional stronghold, the firm is also the front-runner to grab a big share of the rapidly-growing obesity market. A combination of changing market dynamics, ..."
Pages
76
Language
English
Published on
22/11/22
You may also be interested by these reports :
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...